Drugs / KITE-718
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03139370 | Dec 2017 → Jun 2021 | cancer | Kite, A Gilead Company | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-08-17 | Gilead Sciences | Results Kite Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3 gilead.com ↗
Responses were observed in 4 patients, including a complete remission (CR) in a patient with metastatic cervical cancer that is ongoing at 29 months. |
| 2017-01-03 | Gilead Sciences | Regulatory Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6 gilead.com ↗
Kite Pharma, Inc. (Nasdaq: KITE ) today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 trial of KITE-718, a T cell therapy engineered to express T cell receptors (TCRs) that target MAGE A3 and MAGE A6. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03139370 ↗ |
| Modality | Cell therapy | “These cells are genetically modified to make the experimental treatment KITE-718.” NCT03139370 ↗ |